How Biotech Leader Abzena Uses Tech to Meet Medical Needs

There are plenty of ways pharmaceutical companies are working to accelerate the development process, with innovation and technology propelling discovery and driving impact.

Abzena is a leading end-to-end bioconjugate, ADC and complex biologics CDMO+CRO. From discovery through commercial launch, it supports customers with fully integrated programmes — as well as individual services — designed to de-risk and streamline the development of new treatments for patients in need. Research, development and cGMP happens across its global facilities — San Diego, California and Bristol, Pennsylvania in the US and Cambridge in the UK.

CIO Dave Williamson is at the forefront of Abzena’s technological development, leveraging data that is critical to automation, drug discovery and accelerating outcomes. 

A chemist by training, Dave’s career began with a stint in the US Army, which paid for his university studies — an experience that allowed him to travel the world and “go on many different adventures”. 

He says: “I’ve always been fascinated by science, how things work.”

This prompted his move into the pharmaceutical industry, where he has spent the rest of his career to date. In roles across pharmaceuticals, generics and biotech, Dave has been working at the intersection of technology and healthcare for decades, helping with progressing medicines that benefit those underserved.

Now, as Abzena’s CIO, Dave is setting the company’s continued technological development in motion, ensuring the biopharma is data smart and delivering results for its clients and those in need.

 To read the full article in the magazine, click HERE.

Make sure you check out the latest industry news and insights at Healthcare Digital and be part of the conversation at our global conference series, Manufacturing LIVE.

Discover all our upcoming events and secure your tickets today.

Healthcare Digital is a BizClik brand